News
Stay up to date on the latest crypto trends with our expert, in-depth coverage.

1Bitcoin back to record fear levels as it wipes weekend gains2The Funding: Why TradFi giants like BlackRock are buying DeFi tokens now3Will Solana fall another 95%? Why SOL’s bottom looks far away
Paramount submits higher offer for Warner Bros Discovery in bid to block Netflix, source says
101 finance·2026/02/23 22:09

'Ethereum Foundation believes in Defipunk', says org as it forms team to support protocol development
The Block·2026/02/23 22:03

Tenaris Terminates Second Tranche of its USD 1.2 Billion Share Buyback Program
Finviz·2026/02/23 22:00

BioMarin Pharmaceutical's (NASDAQ:BMRN) Q4 CY2025 Sales Beat Estimates
Finviz·2026/02/23 21:54

MediaAlpha (NYSE:MAX) Misses Q4 CY2025 Sales Expectations, But Stock Soars 8.2%
Finviz·2026/02/23 21:51
Keysight forecasts quarterly profit above estimates on strong data center-led demand
101 finance·2026/02/23 21:51

Bitcoin may reverse course and rally to $75K: Here’s how
Cointelegraph·2026/02/23 21:48
Flash
22:07
Better and the well-known investment institution Framework Ventures officially announce the establishment of a strategic partnershipBoth parties will leverage the Sky stablecoin ecosystem to inject up to $500 million into the Better platform. This significant collaboration will fully utilize the technical advantages of the Sky stablecoin ecosystem, providing strong financial support for Better. Through strategic synergy, both parties are committed to promoting innovative applications of digital assets in the field of real estate finance.
22:07
Vir Biotechnology, Inc. announces positive progress in dose expansion cohorts for its research and development projectsThe company has established a clear plan, aiming to officially launch key registrational clinical trials in 2027. This strategic step marks a significant milestone in the development of its core therapies, laying a solid foundation for subsequent regulatory approvals and potential commercialization.
22:05
Astellas Pharma announces that its collaboration agreement terms could bring in up to $1.37 billion in additional funding.The funds will be disbursed in batches based on milestone events such as drug development progress, regulatory approval achievements, and market sales performance. This potential financial injection highlights the company's strategic positioning in the field of innovative therapies and also provides funding support for subsequent research and development.
News